Lazard Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
Lazard Asset Management's RXRX Position: Q3 2026 in Review
Lazard Asset Management reduced its Recursion Pharmaceuticals (RXRX) stake by 49% in Q3 2026, selling an estimated $1.15M and leaving 351,744 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1075.
Lazard Asset Management first reported a position in RXRX in Q4 2021 and has held it in 20 quarters since. The position peaked at $4.23M in Q3 2024. 347 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.
- Lazard Asset Management held 351,744 shares of Recursion Pharmaceuticals worth $1.45M as of Q3 2026.
- Lazard Asset Management sold 340,634 Recursion Pharmaceuticals shares in Q3 2026, an estimated $1.15M.
- Recursion Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q3 2026, its #1075 holding.
- Lazard Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 20 quarters since.
- Lazard Asset Management's Recursion Pharmaceuticals position peaked at $4.23M in Q3 2024.
- 347 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.
Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.